The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
The test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
The companies will develop a smartphone-based platform to offer molecular tests enabling the precision treatment of psychiatric disorders.
The group, made up of three Rennova subsidiaries, will focus on mental and behavioral health, oncology, urology, and cardiovascular disease.
The financing, which comes on the heels of a $30 million Series C round, will be used for operating capital.
The number of institutions offering clinical exome or genome tests to healthy individuals keeps increasing, but the practice remains controversial among medical experts.
The company, which raised the money from Silicon Valley Bank as well as existing shareholders, said it will use the proceeds to expand its business.
The PGx firm can offer its RightMed test in 49 states and plans to seek certification in New York this year.
Inova plans to offer broad and condition-specific PGx gene panels in its specialty clinics and is negotiating with payors for reimbursement.